Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi Ventures
Funding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics (“Veralox”), a preclinical stage company focused on accelerating the development of first-in-class … Read More